EBF vs REGN · P/E 12, rev $394.6M vs P/E 14, rev $14.34B
Ennis Inc (EBF) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Ennis Inc (EBF) is a business equipment & supplies company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EBF revenue for 2025-02-28 was $394.6M. Net income was $40.2M. Revenue was down 6.1% from 2024-02-29 to 2025-02-28. EBF currently screens at market cap $473.9M and trailing P/E 12.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EBF currently screens at market cap $473.9M and trailing P/E 12.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EBF and REGN stock pages for the full models.
Not investment advice.